A promising approach for cancer gene therapy is the combination of adenovirus vectors (AdV) with the suicide gene cytosine deaminase and uracil phosphoribosyl transferase (CDHUPRT). While such vectors have been tested in tumor cell lines and xenograft models, it is not clear how these therapeutic vectors would perform in primary human tumors. We, thus, examined the effect of the combination of a recombinant adenovirus expressing the CDHUPRT (AdCU) with 5-fluorocytosine (5-FC) on primary cancer cells isolated from the ascites or pleural fluids of patients with metastatic cancers. In such models, we have found a direct correlation between the patients' response to 5-FU and the response shown by the cancer cells in vitro, confirming the clinical relevance of this methodology. Our findings demonstrated that this combination was able to kill primary tumor cells, including those that had developed resistance to 5-FU. Furthermore, while proliferating cells were more susceptible to 5-FU, the combination was effective in both rapid and slow proliferating samples. Our study demonstrated that this gene therapy approach could provide an effective therapeutic option for cancers and is not affected by acquired 5-FU resistance. Also of importance is the effectiveness of this gene therapy approach on slower proliferating cells that is typical of the majority of cancers in vivo. This suggests a greater likelihood that it will be effective in a clinical setting.
Introduction
Major advances in the understanding of the growth and development of cancers has led to more effective means of treating the disease, resulting in improved outcomes and higher quality of life. While chemotherapy remains as one conventional approach to cancer treatment, severe limitations still persist. Development of drug resistance is one such limitation that is a major cause of treatment failure and poor prognosis in many cancers. In addition, patients may also experience systemic toxicity that will hinder successful treatment. With the increased knowledge of the molecular mechanisms underlying oncogenesis, there has been an increased interest in gene therapy as an approach for treating cancer. The development of gene therapy as a tool for the treatment of cancer has attracted attention in the past few years, enhanced by the approval of an adenovirus expressing p53 for the treatment of head and neck cancer in China. Another promising platform for cancer gene therapy is the combination of adenovirus vectors (AdV) with the suicide gene comprising the fusion of the cytosine deaminase and uracil phosphoribosyl transferase (CDHUPRT). [1] [2] [3] While such vectors have been tested in tumor cell lines and xenografts in animal models, it is not clear how these therapeutic vectors will perform in primary human tumors, including primary tumors from 5-fluorouracil (5-FU) resistant patients. We thus examined the effect of combining a recombinant adenovirus expressing the CDHUPRT (AdCU) and 5-fluorocytosine (5-FC) drug treatment on primary cancer cells isolated from the ascites or pleural fluids of patients with metastatic cancers.
Many gene therapy approaches to cancer have been based on suicide gene therapy through a gene-directed pro-drug converting enzyme. This involves the introduction into tumor cells of an exogenous enzyme that converts a nontoxic pro-drug into a cytotoxic drug (reviewed in Yazawa et al. 4 and Kirn et al. 5 ). In these approaches, the cytotoxic drug will concentrate at the localized site, thereby increasing the therapeutic index. Also a key feature of many of these approaches, is a bystander effect; that is, the ability of cells that are transduced and exposed to the pro-drug to also kill adjacent untransduced cells by allowing diffusion of the converted cytotoxic drug. The bystander effect is critical due to the current inability to effectively transduce 100% of tumor cells in vivo. [6] [7] [8] Several systems in addition to the CD/5-FC have been examined to date, including the enzyme herpes simplex virus-thymidine kinase (HSV-TK) which converts gangciclovir into GCV triphosphates to interfere with DNA replication, carboxylesterases which activate irinotecan, nitroreductases, carboxypeptidases and purine nucleoside phosphorylases (reviewed in Denny). 9 The vectors tested in this study use the cytosine deaminase (CD) and the uracil phosphoribosyl transferase (UPRT). These vectors have previously shown high efficacy on glioblastoma cell lines, suggesting a potential for the treatment of cancers of the central nervous systems, 10 and possibly cancers of other origins. Through the actions of CD, an enzyme that is present in prokaryotes and fungi but not in multicellular eukaryotes, 11, 12 the benign pro-drug 5-FC is converted to the highly cytotoxic 5-FU. 5-FC is introduced at relatively high concentrations, thus allowing the 5-FU generated at the tumor site to achieve concentrations that are higher than can be systemically administered safely. This system has been further improved by the inclusion of the UPRT that converts 5-FU to 5-fluorouridine monophosphate, the first step of its pathway to activation, similar to the actions of the mammalian orotate phosphoribosyltransferase. 13, 14 5-FU is used in the treatment of many cancers including gastrointestinal, breast, head and neck and colorectal cancers, and exerts its antitumor effects in a number of ways including inhibition of RNA synthesis, inhibition of thymidylate synthase (TS) to inhibit DNA synthesis, and induction of DNA strand breaks through incorporation into DNA. 15, 16 Although 5-FU is effective in treating cancers, development of resistance is common. 17, 18 Toxicity limits its administration at higher concentrations to overcome the resistance. In addition, the bioavailability of 5-FU varies greatly in patients due to the large individual variations, including differences in rates of clearance from the body and in the activities of the dihydropyrimidine dehydrogenase (DPD), the enzyme responsible for degradation of 5-FU. 19 Similarly, there can also be individual variances in the enzyme activity of TS which is inhibited by 5-FU. 20 There is evidence that the suicide gene therapy can overcome these limitations by achieving a high enough drug concentration at the tumor sites to inhibit both DNA and RNA synthesis. Studies of the suicide gene therapy we are investigating here have yielded very promising results on established cell lines and human xenografts in nude mice. 1, 2, [21] [22] [23] [24] [25] However, these models have limited value in predicting the therapeutic effectiveness in a clinical context. The poor predictive value of these model systems arises from the great differences that exist between primary tumor cells and the tumor cell lines developed for research. The rationale for the present study is to characterize and determine the therapeutic potential of this gene therapy system using primary tumors isolated from patients with metastatic cancer. These cancer cells were used soon after removal from the patient so they retained as much of their in vivo features as possible. Previous studies showed that these cells had much slower doubling times that were closer to those seen in patients. 26 As they were used before any selection for growth advantages, they had a mixed genetic background and would contain subpopulations that had inherent resistance to some anticancer agents. More importantly, these cancer cells tend to retain their resistance to the chemotherapeutic agents that were administered to the patients. This allows us to test the gene therapy system on primary cancer cells that developed resistance to 5-FU while the patients were undergoing treatment. We present results to show that the adenovirus-based gene therapy system can be effective against 5-FU-resistant cancer cells and is independent on proliferation rates.
Material and methods

Cell culture and medium
The primary cancer cells from ascites or pleural fluid were isolated as described in Richard et al. 26 After isolation, the cells were cultured in DMEM, containing 10% fetal bovine serum and antibiotics (penicillin (200 U/ml), streptomycin (200 mg/ml) and amphotericin (0.5 mg/ml)) at 371C in a 5% CO 2 incubator.
Bromodeoxyuridine incorporation
Incorporation of bromodeoxyuridine (BrdU) into DNA was used to correlate cell proliferation with sensitivity to 5-FU and to AdCU transduction. The measurement of BrdU uptake was performed as described previously. 26 
Transduction of adenovirus
The recombinant adenovirus expressing either cytosine deaminase (AdCD) and green fluorescent protein (GFP) or CD with uracil phosphoribosyltransferase (AdCU) and GFP were constructed and used as described in Bourbeau et al. 10 Cells were plated out at a density of 100 000 cells in 12-well plates. The next day, the cancer cells were infected with either AdCU or AdCD at a multiplicity of infection (MOI) of 25, 50 and 100. At 2 days post-infection, the cells were analyzed by flow cytometry and the percentage of cells positive for GFP was determined. The cells were also examined under a fluorescent microscope to verify the presence of GFP-positive cells.
Drug and virus treatments and MTT assay 5-FU sensitivity. Sensitivity of the primary cells to 5-FU was determined by the MTT (3-(4,5)-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) assay as described in Richard et al. 26 Primary cancer cells (10 000 cells) were plated in 100 ml medium in each well of a 96-well plate and allowed to adhere overnight. The next day, increasing concentrations of 5-FU was added in quadruplicate and incubated for 6 days at 371C. The MTT assay was then performed essentially as described by Mosmann. 27 Briefly, MTT (Sigma-Aldrich, Oakville, Ontario, Canada) was dissolved in phosphate-buffered saline (PBS) at 5 mg/ ml and filter sterilized. This MTT stock solution was then added to each of the wells (10 ml per 100 ml medium) and incubated for 4 h at 371C. The medium was then removed by aspiration and replaced with 100 ml dimethyl sulphoxide (DMSO) and allowed to sit at room temperature for 10 min. The plates were read using a kinetic microplate reader (Molecular Devices Corporation, Sunnyvale, CA) at a wavelength of 490 nm, and the values were corrected against the blank wells that did not contain any cells. The wells without any 5-FU were used as the untreated control, and the absorbances from the quadruplicate wells were averaged and expressed as a percentage of the control. The statistical evaluations were performed using Microsoft Excel.
Virus treatments. Primary cells were plated out at a density of 10 000 cells per well in 96-well plates. The next day, cells were transduced with either AdCD or AdCU at a MOI of 25, 50 or 100 in 50 ml for 5 h. 5-FC (50, 100 or 500 mM) or increasing concentrations of 5-FU was then added to the appropriate wells at a final volume of 150 ml, and the cells were incubated for 6 days. The viable cells were measured using the MTT assay as described above. Untreated cells and cells treated with either 5-FC or AdCD or AdCU alone were used as controls.
Results
Sensitivity of primary cancer cells to 5-FU
Before evaluating the efficacy of the combination treatment of AdCU/5-FC that exhibits its therapeutic action through the conversion of 5-FC into 5-FU, we characterized our primary cells for their sensitivity to 5-FU.
We have collected samples from six patients with cancers of different origins: two colon (A-Col1; A-Col2), one ovarian (P-Ov1), one non-Hodgkin lymphoma (A-Nhl1), one breast (A-Br1) and one appendix (A-App1) as listed in Table 1 . Of these, the patients with cancers of the appendix (A-App1), breast (A-Br1) and one of the patients with colon cancer (A-Col2) had been previously treated with 5-FU as part of their chemotherapeutic regiment and had developed resistance during the course of treatment. The other three had been treated with other chemotherapy drugs. The in vitro response to 5-FU treatment, as assessed for viability with the MTT assay, showed that there was a significant difference in the sensitivity of the cells from the patients who failed the 5-FU treatment and the cells from those who had not received the drug (Figure 1 ). At 5-FU concentrations higher than 10 mM, about 70% of the cells from the three 5-FU-resistant patients remained viable, while this concentration reduced the surviving fractions of the sensitive cells to 20-30%. This shows a direct correlation between the chemosensitivity of the primary cells to 5-FU and the patients' response. The resistant cells did not show cross-resistance to other chemotherapeutic agents tested, such as doxorubicin, cisplatin and paclitaxel (data not shown). Figure 2 Effect of AdCD and AdCU on isolated primary cancer cells. Cells isolated from the ascites or pleural fluid of patients were transduced with either AdCD or AdCU at a MOI of 100 for 5 h before addition of 50, 100 and 500 mM 5-FC. Cell viability was assessed after 6 days with the MTT assay (Po0.05 using a two-tailed Student's t-test).
Suicide gene therapy in human primary tumors C Richard et al for 5-FC to between 2 and 25 mM for each of the cancer cell samples. Included among the sensitized cells were the breast (A-Br1) and appendix (A-App1) cancer cells that were shown to be resistant to 5-FU (Figure 1 ). This overcoming of resistance was not dependent on the site of origin of the cancer cells as AdCU plus 5-FC was effective against the colon cancer cells that were both sensitive (A-Col1) and resistant (A-Col2) to 5-FU. As previously reported, [1] [2] [3] 10 the AdCD was much less effective than the AdCU in killing the cells. At an MOI of 100 and 100 mM 5-FC, the surviving fraction was between 30 and 50% whereas at the same concentration with AdCU, the surviving fraction was o20% in all samples. This decreased sensitivity to AdCD treatment is not due to decreased transduction efficiency of the virus since the GFP positive cells were higher in samples treated with AdCD than with AdCU (data not shown). The 5-FU-resistant colon cancer cells A-Col2 exhibited slightly higher resistance to the AdCU gene therapy, with 21% surviving the combination of the AdCU at MOI of 100 and 100 mM 5-FC. Increasing the concentration of 5-FC to 500 mM reduced this surviving fraction to o10%. This limited increased resistance to the gene therapy regime may be due to decreased transduction efficiency of AdCU. At a MOI of 100, only 34% of the A-Col2 cells were positive for GFP, whereas greater than 50% of the other samples were positive at the same MOI (data not shown). These results showed that the CDHUPRT/ 5-FC suicide gene therapy was efficient in sensitizing cancer cells, including those that had acquired resistance to 5-FU.
Role of the UPRT in overcoming the 5-FU resistance
The 5-FC is converted to 5-FU by the actions of the CD portion of the fusion gene used in this approach. Additionally, the therapeutic gene used in the AdCU also contains the UPRT that converts 5-FU to its active intermediate, 5-fluorouridine monophosphate, which is a necessary intermediate in the actions of 5-FU. In the absence of the UPRT, the endogenous enzyme orotate phosphoribosyltransferase (OPRT) converts 5-FU. As our approach is overcoming the 5-FU resistance, we wanted to determine the role played by the UPRT in promoting its efficacy. We first treated the cells with AdCU, followed by 5-FU. As we did not add 5-FC, the action of CD does not come into play and any increased cell death can only be attributed directly to the UPRT activity. As shown in Table 2 , the addition of the AdCU was able to drastically decrease the IC 50 values for 5-FU in each sample, including the three resistant samples. In these resistant samples, the IC 50 was improved by more than 30-fold while the improvement for the nonresistant cells was four-to fivefold. This demonstrates that the addition of UPRT contributes to 5-FU toxicity by (1) compensating for the limited OPRT activity as observed in the nonresistant cells; and (2) overcoming, at least to some extent, the resistance mechanism in the 5-FU resistant cells.
Effect of the cycling rate on the sensitivity to 5-FU One major caveat of using cell lines as models to test antineoplastic agents is the relatively fast division rates of cell lines, compared to tumor cells that could take several weeks, or months, to divide in patients. As our gene therapy approach is based on the cytotoxicity of 5-FU that inhibits DNA synthesis and causes dysfunction in RNA metabolism, we determined the effect of the cycling rates of the cells on the efficacy of our approach. We first compared the sensitivity to 5-FU of cancer cells that were freshly isolated with those that approached replicative senescence. As previously described, 26 the cancer cells isolated from ascites and pleural fluids do not adapt to culture conditions and tend to proliferate slowly, taking about 2 weeks to divide, and eventually becoming senescent after three to five passages. In the example shown in the top panel of Figure 3 , 45% of the freshly isolated ovarian cancer cells (P-Ov1) incorporated BrdU into their DNA after incubating for 6 days. As the cells approached replicative senescence, the proportion of BrdU-positive cells reduced to 5%. Although each of the samples showed some sensitivity, the cycling cells were more susceptible to 5-FU. Concentrations of 5-10 mM were enough to reduce the viable population by 60-70%. In contrast, about 70% of the senescent cells remained viable at concentrations of up to 20 mM 5-FU. With the A-Col1 colon cancer cells, shown in the bottom panel, 62% of the freshly isolated cells incorporated BrdU after 6 days incubation. This proportion was reduced to 17% as the cells approached senescence at the time of the assay. Similar to the ovarian cancer cells, the faster cycling cells were more susceptible to the toxicity of 5-FU, killing about 70% of the cells with a concentration of as low as 5 mM. With cells that were approaching senescence, about 60% were viable at concentrations of up to 20 mM 5-FU. The results show the direct correlation between the rate of cell proliferation and susceptibility to 5-FU.
Effect of the cycling rate on the sensitivity to AdCU/5-FC treatment We examined the dependence of AdCU/5-FC on division rates of the primary cancer cells. Using cells that were in the process of withdrawing from the cell cycle and entering a state of senescence, as indicated by o5% of the cells having BrdU in their nuclei after 6 days incubation, we tested the efficacy of our treatment. Again, these cells, either cycling or approaching senescence, exhibited minimal susceptibility to the toxic effects of 5-FC alone, up to concentrations of 500 mM (Figure 4) . However, when combined with the transduction of the AdCU at MOI of 100, there was a sharp decline in survival of the cancer cells, independent of the rates of cell division. Even at the lower concentration of 100 mM 5-FC, the percentage of viable colon cancer cells decreased to about 25-35%, and this further reduced to o20% in 500 mM 5-FC (top panel). Similarly with the cancer cells of the appendix, the percentage of surviving cells was o20% in 100 mM 5-FC, and this continued to drop to below 10% in 500 mM 5-FC (bottom panel). The results show that the effectiveness of AdCU plus 5-FC was not dependent on the ability of the cells to traverse the cell cycle.
Bystander effect of AdCU Previously, it has been shown that the AdCU construct yields substantial bystander effect in glioblastoma cell lines. 10 As bystander effect is essential for this to be an effective therapy, we tested a range of MOI of AdCU on the primary cancer cells to determine the minimum that would be required for toxicity to 5-FC. As the AdCU coexpresses GFP, transduction efficiency could be measured by flow cytometry and presented as a percentage of cells that expressed GFP. When tested with MOI of AdCU of up to 100, there was an increase in the number of cells that expressed GFP, and this increase corresponded directly with increasing MOI (data not shown). As shown in Figure 5 , cancer cells of different origins had different transduction efficiencies. At the MOI of 50 used in the experiment, the percentage of cells that expressed GFP varied between 20 and 78%, depending on the sample. The lowest transduction efficiency was with A-Col2 where only 21% of the cells were positive for GFP, and the P-Ov1 had the greatest transduction efficiency with 77% of the cells showing positive fluorescence for GFP. In each case, at 500 mM 5-FC, o20% of the cells remained alive after 6-day treatments ( BrdU=45% BrdU=5% Figure 3 Effect of cell division on sensitivity to 5-FU on isolated primary cancer cells. Cells were isolated from the pleural fluid of a patient with ovarian cancer, P-Ov1 (top panel) or from the ascites of a patient with colon cancer, A-Col1 (bottom panel). The sensitivity to 5-FU was determined with the freshly isolated cycling cells, and with cells at a later passage that began to enter senescence. The cycling rate was determined by measuring the percentage of cells that incorporated BrdU into the DNA. The percentage of P-Ov1 cells incorporating BrdU was 45% over the 6-day period when they were freshly isolated and 5% at the later passage. The percentage of A-Col1 cells that incorporated BrdU was 62% when they were cycling and 17% at a later passage (Po0.05). 
Discussion
In this study, we investigated the therapeutic potential of the combination of a replication defective recombinant adenovirus expressing a fusion gene comprising of CD and uracil phosphoribosyltransferase with 5-FC pro-drug in tumor cells isolated from the ascites or pleural fluids of cancer patients. These primary cells were collected from cancer patients that no longer respond to chemotherapy and have developed metastases. Of the six cancer cell samples described here, three were shown to be resistant to 5-FU. These cells were isolated from patients who were treated with chemotherapy that included 5-FU and developed resistance during the course of their treatment. When tested in culture, the cells were also resistant to 5-FU (Figure 1 ), suggesting that the 5-FU-resistance in the patients was due to genetic changes in the cancer cells and not to other extraneous factors, such as elevated clearance from the body or inadequate access to the tumor. Several genes associated with 5-FU tolerance have been identified in cell lines and are being examined in clinical samples. 19, 20, 28, 29 These 5-FU-resistant cell lines were isolated by continuous incubation with the drug, 30 mimicking the process of development of resistance in cancer patients treated with 5-FU. In this study, the cancer cells had developed their resistance to 5-FU in the patients, and this genotype remained after isolation and culture of the cancer cells in vitro (Table 1 and Figure 1 ). Efforts are currently underway to determine if the genetic changes in these cells are similar to those responsible for 5-FU resistance in cultured cell lines. Genes that have been reported to be involved include TS, DPD and thymidine phosphorylase. The cancer cells isolated from the ascites or pleural fluid did not exhibit cross-resistance to chemotherapy agents that were not part of the patients' chemotherapy regime. Furthermore, the cancer cells isolated from patients treated with other chemotherapy agents were sensitive to 5-FU, indicating that the results obtained with the MTT assay were consistent with what was happening to the patient. Of importance, we have demonstrated that the treatment with AdCU/5-FC was very effective in killing the primary cancer cells, including those that were resistant to 5-FU. These finding have addressed two critical issues in predicting the clinical potential of this approach: (1) that this approach is potentially effective on primary human tumors; and (2) that it can overcome acquired 5-FU resistance.
One key differentiating feature of primary tumors from established cell lines is the slower rate of cell division in clinical tumors. The primary cancer cells used in this study have a much lower proliferation rate than cultured cell lines, and therefore represent a better model than fast dividing cell lines. Although the exact mechanism of cytotoxicity of 5-FU on primary cancers in patients is not known, experiments with transformed cell lines showed that the cytotoxic activity of 5-FU depends on DNA synthesis and replicative rates, similar to most other anticancer agents. However, it has been estimated that o10% of neoplastic epithelial cells are proliferating at any given time. 31 Hence, treatment with 5-FU would kill only a small percentage of the cancer cells and would allow for the selection of chemoresistance. In addition, dose-limiting toxicity precludes the administration of higher concentrations of 5-FU. In this study, we have demonstrated that, as opposed to chemotherapy with 5-FU which is dependent on cell proliferation, the AdCU/ 5-FC efficacy was as effective in slowly dividing cells (Figure 4) . Biochemical studies have shown that 5-FU can impair both DNA and RNA through direct incorporation or by the formation of fluoro-sugar derivatives. The concentration range of 5-FU currently used are likely to be effective in inhibiting the TS leading to inhibition of DNA synthesis, but may not be sufficient for impairing the RNA metabolism pathway. Using the AdCU gene therapy, we were able to use 10-to 20-fold higher concentrations of 5-FC, thus allowing for much higher concentrations of 5-FU at the tumor site through the conversion by AdCU. At such concentrations, adequate levels of 5-FU could be reached locally to affect both DNA and RNA pathways affecting both rapidly and slowly replicating cells.
In addition, we have confirmed the presence of a bystander activity with those primary cells, as only a minimal transduction efficiency was sufficient for killing majority of the cells ( Figure 5 ). We also confirmed that the fusion gene expressing both the CD and UPRT activity was superior to the AdCD alone (Figure 2 ). Finally, we have shown that the UPRT activity bolsters cell death in both resistant and nonresistant cancer cells. The dramatic increase in the cytotoxicity of 5-FU in resistant cells, when combined with AdCU alone, suggested that the OPRT activity might be impaired in A-Br1 (38%) Figure 5 Bystander activity in isolated primary cells. Cells isolated from the ascites or pleural fluid of the patients were transduced with AdCU at a MOI of 50 for 5 h. 5-FC was added at varying concentrations and the cell viability was assessed after 6 days using the MTT assay. The incorporation of AdCU was examined 2 days after transduction by determining the number of cells positive for GFP by flow cytometry. The percentage of cells positive for GFP is indicated in the figure legend for each sample (Po0.05 using a two-tailed Student's t-test).
Suicide gene therapy in human primary tumors C Richard et al 5-FU-resistant tumors. Chung et al. 32 showed that OPRT was one of the enzymes that was downregulated in gastric cell lines that were selected for resistance to 5-FU. Ichikawa et al. 33 recently reported that the relative expression of OPRT tended to be lower in metastatic colorectal cancers that did not respond as well to fluoropyrimidine-based drugs, and proposed that ratio of OPRT to DPD could be used to predict patient response to these drugs.
In this study, we have shown that the AdCU/5-FC was effective as an antineoplastic agent in primary human tumors, further validating the potential of this approach beyond the traditional cell line-based models and xenografts. Our study demonstrated that this gene therapy approach could provide an effective therapeutic option for cancers and is not affected by acquired 5-FU resistance. Also of importance is the effectiveness of this gene therapy approach on slower proliferating cells that is typical of the majority of cancers in vivo. This provides evidence for the likelihood that this approach would be effective in a clinical setting.
